Answers are grounded in this paper and cite their sources.
Background Deep brain stimulation (DBS) is an established treatment for medication-refractory essential tremor (ET); however, the long-term effects of unilateral DBS, particularly on health-related quality of life (HRQoL), have remained uncertain. Therefore, this study compared short-, mid-, and long-term HRQoL and tremor outcomes after unilateral versus bilateral ventralis intermedius/posterior subthalamic area (Vim/PSA) DBS. Methods In this single-centre, registry-based, retrospective study, prospectively collected data of 35 patients with ET were analysed to compare outcomes of unilateral versus bilateral Vim/PSA DBS. Outcomes were assessed at 1, 2–5, and ≥6 years. The primary outcome was HRQoL assessed by the Summary Index of the Quality of Life in Essential Tremor Questionnaire. Secondary outcomes included the 5-dimension 5-level European Quality of Life Questionnaire, Schwab and England Activities of Daily Living Scale, and Fahn-Tolosa-Marin Tremor Rating Scale Parts A, B, and C. Between-group differences were assessed using appropriate parametric and non-parametric tests, while longitudinal outcomes were analysed using repeated-measures ANOVA and ordinal logistic mixed-effects models. Results No significant between-group differences in HRQoL were observed at any follow-up. Bilateral DBS was associated with greater overall tremor reduction, with significant time×group interactions for the FTMTRS score at 1 ( p = 0.048), 2–5 ( p = 0.031), and ≥6 ( p = 0.041) years. Long-term axial tremor control also favoured bilateral DBS ( p < 0.001). In contrast, dominant-side tremor outcomes were comparable between groups, with no significant time×group interactions or group effects. Conclusion Bilateral DBS was associated with greater overall tremor reduction, whereas HRQoL and dominant-side tremor outcomes were comparable between unilateral and bilateral DBS groups across the examined follow-up periods. These findings suggest that unilateral DBS may also provide sustained HRQoL improvement in appropriately selected patients with ET; however, the retrospective design, limited sample size, and clinically selected treatment allocation may limit causal interpretation.
No takes yet. Share an insight, caveat, or question.
Hemeda et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: